Is Egrifta (Tesamorelin) Legal in California? How to Access It Legally
HealthRX.com
Egrifta is FDA-approved; state rules need a separate check
Key numbers
- 1.4 mgEgrifta SV dose per injection, given once daily into the abdomenSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 1.28 mgEgrifta WR dose per injection, given once daily; not substitutable with SVSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 11.6 mgEgrifta WR vial size, which supplies seven daily dosesSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Tesamorelin
At a glance
- FDA status / Approved biologic under BLA 022505; original approval November 10, 2010 [3]
- Current products / Egrifta SV 2 mg vial and Egrifta WR 11.6 mg vial [1][2]
- Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy; not weight loss [1]
- Doses / Egrifta SV 1.4 mg; Egrifta WR 1.28 mg; not substitutable [2]
- Compounding / In no category of FDA's pharmacy or outsourcing-facility lists; not on the significant-safety-risk list [4][5][6]
What is Egrifta approved for?
Egrifta SV and Egrifta WR are indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy [1][2]. The label says long-term cardiovascular safety has not been established and that the drug is not indicated for weight loss management because its effect on weight is neutral [1].
Egrifta SV is 1.4 mg (0.35 mL) injected subcutaneously into the abdomen once daily [1]. Egrifta WR is 1.28 mg (0.16 mL) once daily, and one 11.6 mg vial supplies seven daily doses [2]. The Egrifta WR label states that the two products are not substitutable [2].
What does FDA say about compounded tesamorelin?
Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [7][8]. Tesamorelin is not on FDA's significant-safety-risk bulk list, and it appears in no category of FDA's list for state-licensed pharmacies and physicians or its list for outsourcing facilities [4][5][6]. FDA has therefore made no category-based statement about compounding it. Tesamorelin is also not among the six peptides in HHS's draft enforcement-discretion policy for compounding [7][8]. It is the active ingredient in the FDA-approved products Egrifta SV and Egrifta WR [1][2][3].
Dr Alex Tatem on why tesamorelin is the most proven, not the strongest
Dr. Alex Tatem argues that tesamorelin is the most clinically proven peptide he has covered, pointing to its phase three trials and the visceral fat reductions seen on CT scans. He says it mostly moves fat out of the belly while the scale barely changes. He is skeptical of its sleep and muscle claims, saying Sermorelin has better sleep data at a far lower price. He links the high cost to the FDA's forty amino acid rule, which classifies tesamorelin as a biologic and keeps it out of the compounding system. In his view, people with HIV-associated lipodystrophy should go get it, while others with visceral fat should measure their waist, liver, growth factor levels and A1C if they try it.
Who is speaking?
Dr. Alex Tatem. Host of the Dr. Alex Tatem channel, who calls himself a urologist in the video Background
What are the main label warnings?
Both labels contraindicate tesamorelin in people with disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity to tesamorelin or the product's excipients, and pregnancy [1][2]. In rat studies at roughly 2 to 4 times the human exposure, offspring developed hydrocephalus [1][2].
The label also warns about elevated IGF-1, glucose intolerance or diabetes, fluid retention, hypersensitivity reactions and injection-site reactions [1]. Among patients treated for 26 weeks, 47% had IGF-1 above 2 standard deviation scores and 36% above 3 SDS [1]. HbA1c of 6.5% or higher developed in 5% of tesamorelin patients versus 1% on placebo, a hazard ratio of about 3.3 (95% CI 1.4 to 9.6) [1].
Questions worth asking
Frequently asked questions
Is Egrifta legal in California?
Can tesamorelin be prescribed for weight loss?
Can a compounding pharmacy supply tesamorelin?
What dose does the label give?
References
Show all 9 referencesHide references
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Drugs@FDA: FDA-Approved Drugs.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- Official web page.
- Dr. Alex Tatem. Tesamorelin: The Peptide That Changes Your Body Without Changing Your Weight. Accessed 2026-11-11.